This grant, offered by the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative, aims to establish a Clinical Trial Data Processing, Analysis, and Coordination Center (CTDPACC). The CTDPACC will provide essential executive management, direction, overall coordination, and robust data processing and analysis support for the Clinical High Risk for Psychosis Clinical Trial Network. The Network’s primary objective is to validate the effectiveness of various drug development tools, including biomarkers, algorithms, and clinical outcome measures, which were initially evaluated within the AMP SCZ project. Specifically, this grant will enable the CTDPACC to support the Network in conducting a focused 12-16 week Proof of Principle (PoP) trial. This trial will utilize one or more compounds that are already prepared for Phase 2 testing, furthering the development of new treatments for psychosis.
Opportunity ID: 349227
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-MH-24-151 |
| Funding Opportunity Title: | Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.242 — Mental Health Research Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 12, 2023 |
| Last Updated Date: | Jul 12, 2023 |
| Original Closing Date for Applications: | Oct 17, 2023 |
| Current Closing Date for Applications: | Oct 17, 2023 |
| Archive Date: | Nov 22, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. see NOFO for eligibility details |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of CTDPACC is to support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial. The Clinical High Risk for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center (CTDPACC) will provide executive management, direction, and overall coordination, including data processing and analysis to support the Clinical High Risk (CHR) for Psychosis Clinical Trial Network companion FOA. That Network validates the utility of drug development tools (biomarkers, algorithms, clinical outcome measures) previously assessed in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) project. The CTDPACC will support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial utilizing a Phase 2 ready compound or compounds. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-151.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 349227 Full Announcement-RFA-MH-24-151 -> RFA-MH-24-151-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00282516 | Sep 17, 2023 | Oct 17, 2023 | View |
Package 1
Mandatory forms
349227 RR_SF424_5_0-5.0.pdf
349227 PHS398_CoverPageSupplement_5_0-5.0.pdf
349227 RR_OtherProjectInfo_1_4-1.4.pdf
349227 PerformanceSite_4_0-4.0.pdf
349227 RR_KeyPersonExpanded_4_0-4.0.pdf
349227 RR_Budget_3_0-3.0.pdf
349227 PHS398_ResearchPlan_5_0-5.0.pdf
349227 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
349227 RR_SubawardBudget30_3_0-3.0.pdf
349227 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
